Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 24, Issue 6, Pages -Publisher
WILEY
DOI: 10.1111/tid.13835
Keywords
breakthrough infection; COVID-19; hematologic malignancy
Categories
Funding
- California Department of Public Health [NU50CK000539]
- National Institutes of Health [R33AI129455]
- National Heart, Lung and Blood Institute [K23HL138461-01A1]
- United States Centers for Disease Control [75D30121C10991]
- Innovative Genomics Institute Canadian Institutes of Health Research
Ask authors/readers for more resources
In this single-center retrospective cohort study, there was no difference in the severity of COVID-19 disease between vaccinated and unvaccinated patients with hematologic malignancies. Recent anti-B-cell therapy was associated with more severe illness.
The effect of vaccination on severity of subsequent COVID-19 in patients with hematologic malignancies (HMs) is unknown. In this single-center retrospective cohort study, we found no difference in severity of COVID-19 disease in vaccinated (n = 16) versus unvaccinated (n = 54) HM patients using an adjusted multiple logistic regression model. Recent anti-B-cell therapy was associated with more severe illness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
